Home › Funds › MPM BioImpact LLC › EWTX

MPM BioImpact LLC position in EWTX

EDGEWISE THERAPEUTICS INC · Health Care

MPM BioImpact LLC reported holding 1,620,780 shares of EWTX (EDGEWISE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$65.9M, representing 4.02% of its reported portfolio and ranking #6 among its reported holdings. MPM BioImpact LLC has disclosed EWTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.62M sh
Reported value held$65.85M
Portfolio Weight4.02%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MPM BioImpact LLC's EWTX position evolved

MPM BioImpact LLC first disclosed a stake in EWTX in Q1 2024 at 441,259 shares (US$8.0M). The position peaked in Q2 2026 at 1,620,780 shares, worth US$65.9M. Across 10 filings, MPM BioImpact LLC increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,620,780 shares valued at US$65.9M — a reduction of -39,916 shares quarter over quarter.. Notable position changes include a 68% increase in Q2 2024 (shares rose 48% over the following quarter), a 56% increase in Q2 2025 (shares rose 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 441.26K $8.05M New
Q2 2024 740.66K $13.34M Add
Q3 2024 917.17K $24.48M Add
Q4 2024 1.08M $28.82M Add
Q1 2025 1.11M $24.32M Add
Q2 2025 1.72M $22.56M Add
Q3 2025 1.72M $27.91M Hold
Q4 2025 1.66M $41.08M Reduce
Q1 2026 1.66M $52.31M Hold
Q2 2026 1.62M $65.85M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About EWTX and 13F data

EWTX (EDGEWISE THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in EWTX — the largest reported positions include ORBIMED ADVISORS LLC (US$630.5M), Paradigm Biocapital Advisors LP (US$415.1M), RA CAPITAL MANAGEMENT, L.P. (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding EWTX

All EWTX fund holders →

FAQ

How long has MPM BioImpact LLC held EWTX?

MPM BioImpact LLC has disclosed EWTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is MPM BioImpact LLC's current position in EWTX?

As of Q2 2026, MPM BioImpact LLC holds 1.62M shares of EWTX (EDGEWISE THERAPEUTICS INC), valued at $65.85M, representing 4.02% of its reported portfolio and ranking #6.

Has MPM BioImpact LLC been buying or selling EWTX?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in EWTX. The position peaked in Q2 2026 at 1.62M shares.

Which other funds hold EWTX?

Other major institutional holders of EWTX include ORBIMED ADVISORS LLC, Paradigm Biocapital Advisors LP, RA CAPITAL MANAGEMENT, L.P., among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.